MK-8527

• Description:

  MK-8527 is an orally active HIV inhibitor and nucleoside reverse transcriptase translocation inhibitor (NRTTI) with antiviral activity. MK-8527 has a similar inhibitory mechanism to ISL (HY-104012) [1][2][3][4].

• UNSPSC:

  12352005

• Target:

  HIV; Reverse Transcriptase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/mk-8527.html

• Purity:

  99.02

• Solubility:

  DMSO : 116.67 mg/mL (ultrasonic)

• Smiles:

  OC[C@]1(C#C)[C@@H](O)C[C@H](N2C3=NC(Cl)=NC(N)=C3C=C2)O1

• Molecular Formula:

  C13H13ClN4O3

• Molecular Weight:

  308.72

• References & Citations:

  [1]Gillespie SW, et al. Islatravir: evaluation of clinical development for HIV and HBV. Expert Opin Investig Drugs. 2024 Feb;33 (2) :85-93.|[2]Liu AY, et al. CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases. Top Antivir Med. 2024 Jul 17;32 (3) :447-482.|[3]Gunaratne SH, et al. CROI 2024: The Challenges of Sustained Viral Suppression, Advanced HIV Disease, and Ending the HIV Epidemic Targets. Top Antivir Med. 2024 Aug 12;32 (4) :542-567.|[4]Zhernov YV, et al. Microbicides for Topical HIV Immunoprophylaxis: Current Status and Future Prospects. Pharmaceuticals (Basel) . 2024 May 22;17 (6) :668.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [1810869-23-8]